ARS Pharmaceuticals, Inc. (SPRY) Q2 2026 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Ars Pharmaceuticals, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:05.315 Good afternoon and welcome to ARS Pharma's second quarter 2026 00:00:05.315 -- 00:00:10.699 earnings conference call. At this time, all participants are in a listen-only mode. 00:00:10.699 -- 00:00:15.062 After the company's prepared remarks, we will open the line for questions. 00:00:15.062 -- 00:00:17.945 Please be advised that today's conference is being recorded. 00:00:17.945 -- 00:00:22.988 I will now turn the call over to Monique Allaire, IR representative 00:00:22.988 -- 00:00:26.670 for the company. Please go ahead. 00:00:27.743 -- 00:00:29.844 Good afternoon and thank you for joining us. 00:00:29.844 -- 00:00:35.146 With me on the call today is Don Casale, President and CEO of ARS Pharma. 00:00:35.146 -- 00:00:40.067 Kathy Scott, our Chief Financial Officer, will join us for the Q&A session. 00:00:40.067 -- 00:00:44.369 Earlier today, we issued a press release outlining ARS Pharma's corporate priorities 00:00:44.369 -- 00:00:48.590 and commercial highlights and detailing its financial results for the second quarter 00:00:48.590 -- 00:00:50.551 of 2026. That 00:00:50.551 -- 00:00:54.912 press release can be found in the Investors and Media section of the company's website 00:00:54.912 -- 00:00:57.152 at ars-pharma.com. 00:00:57.530 -- 00:01:02.091 Before we begin, please note that today's remarks may contain forward-looking statements 00:01:02.091 -- 00:01:06.912 and actual results may differ materially. Please refer to our press release and SEC filings 00:01:06.912 -- 00:01:12.312 for further risk disclosures. With that, I'll turn the call over to Don. 00:01:12.593 -- 00:01:15.673 Thank you, Monique, and good afternoon, everyone. 00:01:15.673 -- 00:01:20.154 It's an absolute honor to host my first earnings call as CEO. 00:...